# Goodrx (GDRX) — Earnings

GDRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gdrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.08 |
| EPS estimate | $0.08 |
| EPS surprise | +0.38% |
| Revenue surprise | +3.72% |
| Revenue | $200.4M |
| Revenue estimate | $193.2M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1809519/000180951926000152/gdrx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/be64f0c9-7f1e-cd59-a8af-2ef838b388ce.html) |

GoodRx reported Q2 2026 results on August 5, 2026. EPS was $0.08, a hair above the $0.08 estimate, with a surprise of 0.38%. Revenue was $200.4 million, above the $193.2 million consensus. Compared with Q2 2025, EPS slipped from $0.09 and revenue dipped 1.3% from $203.1 million.

The table shows a business with very stable results. Quarterly revenue has stayed between $180.0 million and $213.3 million throughout, and EPS between $0.06 and $0.10. Annual EPS was $0.30 in 2022, $0.28 in 2023, $0.33 in 2024 and $0.35 in 2025. Annual revenue moved in a narrow band, from $750.3 million to $796.9 million. First-half 2026 revenue of $394.4 million was about 2.9% below the same period of 2025. Every quarter was profitable. GoodRx beat EPS estimates in 11 of 20 quarters, but Q2 2026 ended a run of eight straight misses. Revenue topped the consensus 15 times.

Third-quarter results came between November 4 and November 10 in each of the past five years. That points to early November 2026 for the next report, which will show whether revenue returns to year-over-year growth.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.08 | $0.08 | 0.38% | $193.2M | $200.4M |
| Q1 2026 | May 6, 2026 | $0.07 | $0.07 | -2.64% | $185.4M | $194.0M |
| Q4 2025 | Feb 25, 2026 | $0.09 | $0.09 | -1.75% | $193.3M | $194.8M |
| Q3 2025 | Nov 4, 2025 | $0.09 | $0.08 | -11.41% | $194.5M | $196.0M |
| Q2 2025 | Aug 6, 2025 | $0.10 | $0.09 | -9.09% | $205.9M | $203.1M |
| Q1 2025 | May 7, 2025 | $0.10 | $0.09 | -5.36% | $202.2M | $203.0M |
| Q4 2024 | Feb 27, 2025 | $0.09 | $0.09 | -1.32% | $199.8M | $198.6M |
| Q3 2024 | Nov 7, 2024 | $0.09 | $0.08 | -7.94% | $195.7M | $195.3M |
| Q2 2024 | Aug 8, 2024 | $0.09 | $0.08 | -8.05% | $200.5M | $200.6M |
| Q1 2024 | May 9, 2024 | $0.08 | $0.08 | 5.54% | $196.1M | $197.9M |
| Q4 2023 | Feb 29, 2024 | $0.07 | $0.08 | 18.52% | $194.3M | $196.6M |
| Q3 2023 | Nov 9, 2023 | $0.06 | $0.06 | 3.27% | $188.5M | $180.0M |
| Q2 2023 | Aug 9, 2023 | $0.06 | $0.07 | 15.70% | $186.8M | $189.7M |
| Q1 2023 | May 10, 2023 | $0.06 | $0.07 | 25.22% | $182.1M | $184.0M |
| Q4 2022 | Feb 28, 2023 | $0.05 | $0.07 | 52.17% | $178.5M | $184.1M |
| Q3 2022 | Nov 8, 2022 | $0.04 | $0.07 | 65.09% | $185.0M | $187.3M |
| Q2 2022 | Aug 8, 2022 | $0.04 | $0.06 | 52.28% | $184.7M | $191.8M |
| Q1 2022 | May 9, 2022 | $0.08 | $0.10 | 22.40% | $200.5M | $203.3M |
| Q4 2021 | Feb 28, 2022 | $0.10 | $0.09 | -9.00% | $217.5M | $213.3M |
| Q3 2021 | Nov 10, 2021 | $0.09 | $0.09 | 3.21% | $194.8M | $195.1M |

## Frequently Asked Questions

### When did Goodrx (GDRX) last report earnings?

Goodrx last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did GDRX beat earnings estimates?

Yes. Goodrx reported EPS of $0.08 for Q2 2026 against a $0.08 estimate — a 0.38% beat.

### How much revenue did GDRX report last quarter?

Goodrx reported $200.4M in revenue for Q2 2026, against a consensus estimate of $193.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).